Edition:
United States

AbbVie Inc (ABBV.K)

ABBV.K on New York Consolidated

65.65USD
23 Mar 2017
Change (% chg)

-- (--)
Prev Close
$65.65
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
7,244,387
52-wk High
$68.12
52-wk Low
$55.06

Latest Key Developments (Source: Significant Developments)

Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067
Wednesday, 22 Mar 2017 02:31am EDT 

Galapagos NV : Initiates Phase 1 study with novel CF potentiator GLPG3067 . Triggers a $7.5 million milestone payment from AbbVie . Third potentiator in growing portfolio of cystic fibrosis drug candidates . Aim of the phase 1 study is to evaluate the safety, tolerability and pharmacokinetics of oral single and multiple ascending doses of GLPG0367 . Safety and tolerability of the combination of GLPG3067 and GLPG2222 will also be evaluated. ."we plan to initiate multiple studies within our cf portfolio in the course of this year, as we get closer to our goal of initiating a patient evaluation of a triple combination therapy by mid-2017." - CSO.  Full Article

Abbvie CEO Richard Gonzalez's FY 2016 total compensation was $21 mln
Monday, 20 Mar 2017 12:51pm EDT 

Abbvie Inc : CEO Richard Gonzalez's FY 2016 total compensation was $21.0 million versus $20.8 million in FY 2015 - sec filing . Abbvie inc - CFO William J. Chase's 2016 total compensation was $8.8 million versus $7.6 mln in 2015 - sec filing . EVP Laura Schumacher's FY 2016 total compensation $8.22 million versus $7.31 million in FY 2015 .Abbvie Inc - Chief Scientific Officer Michael E. Severino's 2016 total compensation was $7.2 million versus $6.6 million in 2015 - sec filing.  Full Article

Abbvie granted priority review in Japan for its investigational regimen of Glecaprevir
Tuesday, 14 Mar 2017 08:00am EDT 

Abbvie Inc : Abbvie granted priority review in Japan for its investigational regimen of Glecaprevir/Pibrentasvir (G/P) for the treatment of all major genotypes of chronic hepatitis c .Priority review follows EMA accelerated assessment and U.S. FDA priority review designations in December 2016 and January 2017 respectively.  Full Article

Abbvie sets quarterly cash dividend of $0.64 per share
Thursday, 16 Feb 2017 12:41pm EST 

AbbVie Inc : Maintains quarterly dividend .Sets quarterly cash dividend of $0.64 per share.  Full Article

Neurocrine Biosciences reports Q4 loss per share $0.51
Tuesday, 14 Feb 2017 04:24pm EST 

Neurocrine Biosciences Inc : Neurocrine Biosciences reports year-end 2016 results and provides investor update for 2017 . Q4 loss per share $0.51 . Q4 earnings per share view $-0.56 -- Thomson Reuters I/B/E/S . Neurocrine Biosciences Inc- Revenues from milestones under abbvie agreement for 2017 are expected to be $30 million .Neurocrine Biosciences-2017 ongoing operating expenses should approximate $230 million to $240 million, exclusive of $30 million up-front fee for in-licensing opicapone.  Full Article

Abbvie Inc reports Q4 GAAP earnings per share $0.85
Friday, 27 Jan 2017 07:48am EST 

Abbvie Inc : Abbvie reports full-year and fourth-quarter 2016 financial results . Q4 GAAP earnings per share $0.85 . Q4 revenue $6.796 billion versus I/B/E/S view $6.91 billion . Q4 earnings per share view $1.20 -- Thomson Reuters I/B/E/S . Sees FY 2017 adjusted earnings per share $5.44 to $5.54 . Sees FY 2017 GAAP earnings per share $4.55 to $4.65 . Q4 adjusted earnings per share $1.20 . Abbvie Inc qtrly total Humira sales $4,292 million versus $3,717 million . FY2017 earnings per share view $5.47 -- Thomson Reuters I/B/E/S . Abbvie Inc - 2017 adjusted diluted EPS guidance excludes $0.89 per share of intangible asset amortization expense and other specified items .Abbvie qtrly worldwide adjusted net revenues of $6.784 billion increased 6.9 percent, excluding 0.2 percent unfavorable impact from foreign exchange rate fluctuations.  Full Article

Abbvie initiates phase 2 clinical trial programs for ABBV-8e12
Wednesday, 25 Jan 2017 08:00am EST 

Abbvie Inc :Abbvie initiates phase 2 clinical trial programs for ABBV-8e12, an investigational anti-tau antibody, in early alzheimer's disease and progressive supranuclear palsy.  Full Article

AbbVie, Genomics Medicine and WuXi NextCODE announce Population Genomics alliance
Monday, 9 Jan 2017 08:05am EST 

AbbVie Inc :Abbvie - Co, Genomics Medicine Ireland, WuXi NextCODE announce Population Genomics alliance; financial terms were not disclosed.  Full Article

Abbvie announces four new collaborations and investments with healthcare companies
Monday, 9 Jan 2017 08:00am EST 

Abbvie Inc :Abbvie Inc - announced four new collaborations and investments with healthcare companies.  Full Article

AbbVie, Lurie Cancer Center to collaborate on multi-year cancer research agreement
Monday, 5 Dec 2016 08:50am EST 

AbbVie Inc :AbbVie and Northwestern University's Lurie Cancer Center to collaborate on multi-year cancer research agreement.  Full Article

More From Around the Web

BRIEF-Abbvie CEO Richard Gonzalez's FY 2016 total compensation was $21 mln

* CEO Richard Gonzalez's FY 2016 total compensation was $21.0 million versus $20.8 million in FY 2015 - sec filing